Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. - Wikidata - wikimedia - TriplyDB

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

http://www.wikidata.org/entity/Q30557865

about

Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy Clinical update on cancer: molecular oncology of head and neck cancer Immune biomarkers of anti-EGFR monoclonal antibody therapy Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.Bevacizumab plus cisplatin and helical tomotherapy in treatment of locally advanced nasopharyngeal carcinoma Cancer therapy and cardiovascular risk: focus on bevacizumab.Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma.The Proton-Sensing G-Protein Coupled Receptor GPR4 Promotes Angiogenesis in Head and Neck Cancer Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies.EGFR regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation.Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer Predictive biomarkers to anti-VEGF therapy: progress toward an elusive goal Cetuximab: its unique place in head and neck cancer treatment Promising systemic immunotherapies in head and neck squamous cell carcinoma.Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients.Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients.Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer.Squamous carcinoma of the ovary.Introducing Cytology-Based Theranostics in Oral Squamous Cell Carcinoma: A Pilot Program.Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma.Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck.Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.3q26-29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes.Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma.Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed.

P2860

Q26765429-6846FDAD-29CA-42CC-BEA0-5C8FEB586EB4 Q26773795-C9F1C204-676F-4788-9A34-5EB1468013D7 Q26782255-7822FDFA-FD52-4DAA-8FBF-2A0E5DB7AAEF Q26993238-25943DBB-96A5-437D-92C5-431FBD876EC0 Q33695197-8FE9BDDC-B8A2-4A87-9BDA-9B324245C1A0 Q34723594-0866191A-B069-4331-8356-217FEDD7927F Q34781374-43A5A0C2-9273-4AB4-A859-F5B79D788DBF Q35091386-1716B1A1-3963-46F0-BAF0-249B0A553BC2 Q35463538-A77986D1-CF7C-45BF-B6DB-16EB12D633AD Q35693308-2560B2F9-C819-452C-B75F-A4AEDF497CC6 Q35694417-5FBACAF4-42CA-40EE-8DBB-336873CC78B4 Q35703835-CF99B71B-47F2-4DB6-A62D-1AF512FAEB02 Q35912079-A13F77B9-D63A-4669-9489-6550751394EE Q35989833-240D7821-6BE9-45C1-8E1E-F7D0E4877792 Q36216452-67153613-9934-4184-A722-428ED9546D44 Q36360133-31E16EFD-2286-4D2C-8F6E-5E2BDA3AF77C Q36506995-EB8C05AE-790C-4ED8-8C9D-7B247F179977 Q36632312-189B7A1E-9287-4DF0-9307-A24DA4E29F4B Q36880604-D0D07904-9274-420B-A487-6E1E48383DE9 Q36883848-58E2E4A7-8FA6-4351-A44E-D6622542FCDF Q37024656-25F5710F-B954-4EE0-8A6F-9DAEFC2D6C3B Q37268981-C4A652D9-AE19-4D5F-BFAD-9DFDEBD40C86 Q37329315-F10A9E42-8A18-4C57-B07B-86253B32A9B2 Q37689066-B5BDBF29-0952-43C0-BEEF-2CE9883C5498 Q37703226-BCABAEAD-1C3A-4AE1-935B-826735263DC9 Q38130312-74C5A1BD-2252-4D6C-8260-BD54310971DA Q38162129-B2DFA80A-F6EC-48F3-BF9F-37E932E3831E Q38221292-5DF84A3D-426B-4EF2-9CFA-FCE872276521 Q38225877-B42F7920-F689-470E-9E13-D9F512A69233 Q38240998-EBA8C11C-FE98-4459-9DB4-0A9651107EDD Q38262616-C7C9F5FC-31B6-40AF-943D-8AD23F0B0E6A Q38383481-EB4C22CA-A5E1-4A9A-9BB3-C49E9F9809E6 Q38489938-210E7521-B042-4459-B2A4-FD39278AEBB0 Q38838071-887F2B56-EBAD-4704-A22E-A0DF3DC6F1A2 Q38855031-069745E9-1FC7-437A-90C6-6507533352D2 Q38892486-798D4EE5-142E-47EF-81DD-ED31A28B85D7 Q39186868-4870FAA8-EA73-4157-BE23-5E9783644BEE Q40196342-FEF61359-F2AA-4B92-BB6C-E4DB8C580A5F Q41141076-C9AEACD2-CE05-4FA1-81C8-E5B75A6DA411 Q41339198-19DAE988-BF0A-4FC9-8752-C5E1719C6F68

P2860

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

http://www.wikidata.org/entity/Q30557865

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Cetuximab and bevacizumab: pre ...... arcinoma of the head and neck.

@ast

Cetuximab and bevacizumab: pre ...... arcinoma of the head and neck.

@en

type

label

Cetuximab and bevacizumab: pre ...... arcinoma of the head and neck.

@ast

Cetuximab and bevacizumab: pre ...... arcinoma of the head and neck.

@en

prefLabel

Cetuximab and bevacizumab: pre ...... arcinoma of the head and neck.

@ast

Cetuximab and bevacizumab: pre ...... arcinoma of the head and neck.

@en

P1433

Q30557865-AB0B9018-54A7-4702-9808-0A6E0AC0A683

P1476

Q30557865-4ED53644-0E18-4FF1-9F45-196D798ED58C

P2093

Q30557865-0BFB2D9E-2FBE-4C24-8EEF-B0A2A6918B58

Q30557865-2A9BD63C-245B-4B42-97A0-EA00969BC4C0

Q30557865-38C7DF6D-76B8-4CED-978A-2443320155E5

Q30557865-51496829-6C71-4FE9-92C1-5611573B9012

Q30557865-6E1C6239-7B70-4635-A69D-E7AEE544F416

Q30557865-90E930C5-A78C-4702-BDF6-1F42F38DF740

Q30557865-9B882478-1189-4D96-B142-90D6EF126FED

Q30557865-A5CB917E-9B2B-4296-81FD-E1190153465B

Q30557865-AEC709B5-D0CD-450D-B8B7-1F2EBE5E7AF0

Q30557865-B4BB0108-5B10-43D1-8F60-117CAC8A4DA0

P2860

Q30557865-0032BFBD-1DBD-47F9-9A07-5399C219FD38

Q30557865-017908A6-B36E-4DE3-A290-B28C25705FDE

Q30557865-0455AED8-D4BA-4B13-B55C-C6EADD233D69

Q30557865-0B91A152-7E27-41F8-AAB1-410EFBACB0F3

Q30557865-0F2A92DE-3E30-4B03-B2F8-33F4A8DBE274

Q30557865-1AA0821A-ED1C-4BCF-ABAE-22B5B8501701

Q30557865-2338C562-306F-459B-A21A-257D75722689

Q30557865-2EAF88E7-2037-47B5-8820-AAC76505C85A

Q30557865-33CD1785-E172-4D91-A8FB-ED46D330B788

Q30557865-3E5B3673-033B-427E-BC4E-020DA9A857E8

P304

Q30557865-D7B0A08B-2AEF-411C-977D-6C9C319853F1

P31

Q30557865-BDBDBF3D-5499-41B6-BC38-CC1F88515BF7

P356

Q30557865-6B29A330-4BDE-477E-8BBD-068AD5235287

P433

Q30557865-BFFC6AE4-03DD-40F8-8659-2EAE4C6323BE

P478

Q30557865-EAC5F8ED-C3F9-4002-989A-80EC2CB48D21

P577

Q30557865-C4B5D08F-51AD-47C9-ACE5-B5073A632C2C

P698

Q30557865-D1C328C3-FD23-4948-990F-6719B35AD934

P921

Q30557865-60855D06-3F6D-4B00-AD74-367748F77A80

Q30557865-66A41094-E5C2-4A17-B888-03DBB8F0CB92

Q30557865-F2C0B8D6-C20B-45FF-90CE-49F627BBB8F5

P932

Q30557865-EB49FC26-9DA8-4C3B-80F6-6FEEA406C140

P356

P1433

Annals of Oncology

P1476

Cetuximab and bevacizumab: pre ...... arcinoma of the head and neck.

@en

P2093

A Argiris

http://www.w3.org/2001/XMLSchema#string

A P Kotsakis

http://www.w3.org/2001/XMLSchema#string

F P Worden

http://www.w3.org/2001/XMLSchema#string

G R Blumenschein

http://www.w3.org/2001/XMLSchema#string

H X Chen

http://www.w3.org/2001/XMLSchema#string

J R Grandis

http://www.w3.org/2001/XMLSchema#string

M K Gibson

http://www.w3.org/2001/XMLSchema#string

M S Kies

http://www.w3.org/2001/XMLSchema#string

P M Harari

http://www.w3.org/2001/XMLSchema#string

P Savvides

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

HGF rescues colorectal cancer cells from EGFR inhibition via MET activation

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

P304

220-225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDS245

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22898037

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3525135

http://www.w3.org/2001/XMLSchema#string